NCT04276441 - A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World | Biotech Hunter

Enrollment

34,244

Participants

Timeline

Start Date

February 25, 2020

Primary Completion Date

January 23, 2025

Study Completion Date

January 23, 2025

Conditions

Atrial Fibrillation

Interventions

DEVICE

Heart healthy Engagement Program with the Apple Watch Series 5 or later

No drug will be given as part of this study. Participants without a diagnosis of AF will be enrolled and a heart healthy Engagement Program delivered via the Heartline app on the iPhone with the Apple Watch Series 5 or later.

DEVICE

Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later

No drug will be given as part of this study. Participants with a diagnosis of AF (taking a DOAC for at least 30 days) will be enrolled and an Anti-Coagulation Adherence Module delivered via the Heartline app on the iPhone with an Apple Watch Series 5 or later.

Trial Locations (1)

94401

Evidation Health, San Mateo